<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28127507</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>10</Month>
        <Day>30</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2162-3279</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Brain and behavior</Title>
          <ISOAbbreviation>Brain Behav</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dalfampridine effects on cognition, fatigue, and dexterity.</ArticleTitle>
        <Pagination>
          <StartPage>e00559</StartPage>
          <MedlinePgn>e00559</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e00559</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/brb3.559</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES">Dalfampridine exerts beneficial effects on walking ability in a subgroup of patients with multiple sclerosis (MS). These patients are termed "responders". Here, we investigated whether the responder status with respect to mobility measures would determine whether dalfampridine treatment exerts a beneficial effect on other MS symptoms. We therefore assessed walking ability, upper limb function, cognition, fatigue, visual evoked potentials (VEPs), depression, and quality of life in patients before and after dalfampridine treatment.</AbstractText>
          <AbstractText Label="METHODS">Patients with MS and impaired mobility were recruited. Maximal walking distance, timed 25 Foot Walk, nine hole peg test, paced auditory serial addition test (PASAT), fatigue severity scale (FSS), VEPs, Beck Depression Inventory (BDI), EuroQol five dimensional questionnaire, and quality of life visual analogue scale were determined before and after 12-14 days of dalfampridine treatment. Repeated measures analysis of variance was applied to determine the effect of dalfampridine treatment.</AbstractText>
          <AbstractText Label="RESULTS">Of the 34 patients who completed the study, 22 patients were responders and 12 patients nonresponders, according to their performance in mobility measures. Treatment effects for the entire patient cohort were observed for PASAT (<i>p </i>= .029) and BDI (<i>p </i>= .032). Belonging to the responder cohort did not predict the response to treatment in these tests. For the FSS, response to dalfampridine treatment was dependent on the responder status (<i>p </i>= .001) while no effects in the total patient cohort were observed (<i>p </i>= .680). Other neurological functions remained unaltered. For VEP latencies, no significant improvements were detected.</AbstractText>
          <AbstractText Label="CONCLUSION">In this study, we observed beneficial effects of dalfampridine on cognition, depression, and fatigue. These effects were not limited to patients who responded to dalfampridine with improved mobility measures. These findings underscore the need to assess the beneficial effects of dalfampridine on neurological deficits in MS patients in additional randomized clinical trials.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Korsen</LastName>
            <ForeName>Melanie</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology University Medicine Greifswald Greifswald Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kunz</LastName>
            <ForeName>Rhina</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology University Medicine Greifswald Greifswald Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schminke</LastName>
            <ForeName>Ulf</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology University Medicine Greifswald Greifswald Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Runge</LastName>
            <ForeName>Uwe</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology University Medicine Greifswald Greifswald Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kohlmann</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Community Medicine University Medicine Greifswald Greifswald Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dressel</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology University Medicine Greifswald Greifswald Germany; Department of Neurology Carl-Thiem-Klinikum Cottbus Cottbus Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D064888">Observational Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>11</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Brain Behav</MedlineTA>
        <NlmUniqueID>101570837</NlmUniqueID>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026902">Potassium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BH3B64OKL9</RegistryNumber>
          <NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015761" MajorTopicYN="N">4-Aminopyridine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005074" MajorTopicYN="N">Evoked Potentials, Visual</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051346" MajorTopicYN="Y">Mobility Limitation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026902" MajorTopicYN="N">Potassium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D034941" MajorTopicYN="N">Upper Extremity</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">cognition</Keyword>
        <Keyword MajorTopicYN="Y">dalfampridine</Keyword>
        <Keyword MajorTopicYN="Y">dexterity</Keyword>
        <Keyword MajorTopicYN="Y">fatigue</Keyword>
        <Keyword MajorTopicYN="Y">multiple sclerosis</Keyword>
        <Keyword MajorTopicYN="Y">symptomatic therapy</Keyword>
        <Keyword MajorTopicYN="Y">visual evoked potentials</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>9</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>1</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28127507</ArticleId>
        <ArticleId IdType="pmc">PMC5256171</ArticleId>
        <ArticleId IdType="doi">10.1002/brb3.559</ArticleId>
        <ArticleId IdType="pii">BRB3559</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>

Allart, E.
, 
Benoit, A.
, 
Blanchard‐Dauphin, A.
, 
Tiffreau, V.
, 
Thevenon, A.
, 
Zephir, H.
, … 
Vermersch, P.
 (2015). Sustained‐released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. Journal of Neurology, 262, 1936–1945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26041616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Chan, A.
, 
Flachenecker, P.
, 
Gold, R.
, 
Haghikia, A.
, 
Hellwig, K.
, 
Hemmer, B.
, … 
Zipp, F.
 (2012). DGN/KKNMS Leitlinie zur Diagnose und Therapie der MS. Retrieved from http://wwwdgnorg/images/stories/dgn/leitlinien/LL_MS_Neu/DGN-KKNMS_MS-LL_20120809_frei_neu4pdf11012013.</Citation>
        </Reference>
        <Reference>
          <Citation>

Cutter, G. R.
, 
Baier, M. L.
, 
Rudick, R. A.
, 
Cookfair, D. L.
, 
Fischer, J. S.
, 
Petkau, J.
, … 
Willoughby, E.
 (1999). Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain, 122, 871–882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10355672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Davis, F. A.
, 
Stefoski, D.
, &amp; 
Rush, J.
 (1990). Orally administered 4‐aminopyridine improves clinical signs in multiple sclerosis. Annals of Neurology, 27, 186–192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2317014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

van Diemen, H. A.
, 
Polman, C. H.
, 
van Dongen, M. M.
, 
Nauta, J. J.
, 
Strijers, R. L.
, 
van Loenen, A. C.
, … 
Koetsier, J. C.
 (1993). 4‐Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. Journal of the Neurological Sciences, 116, 220–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8336169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Dunn, J.
, &amp; 
Blight, A.
 (2011). Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Current Medical Research and Opinion., 27, 1415–1423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21595605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
EuropeanMedicinesAgency
. (2011). European public assessment report (EPAR) for Fampyra. Retrieved from http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002097/WC500109956pdf25102014.</Citation>
        </Reference>
        <Reference>
          <Citation>

Fischer, J. S.
, 
Jak, A. J.
, 
Kniker, J. E.
, 
Rudick, R. A.
, &amp; 
Cutter, G.
 (2001). Multiple Sclerosis Functional Composite (MSFC): Administration and scoring manual. New York, NY: National Multiple Sclerosis Society.</Citation>
        </Reference>
        <Reference>
          <Citation>

Goodman, A. D.
, 
Brown, T. R.
, 
Edwards, K. R.
, 
Krupp, L. B.
, 
Schapiro, R. T.
, 
Cohen, R.
, … 
Blight, A. R.
 (2010). A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Annals of Neurology, 68, 494–502.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20976768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Goodman, A. D.
, 
Brown, T. R.
, 
Krupp, L. B.
, 
Schapiro, R. T.
, 
Schwid, S. R.
, 
Cohen, R.
, … 
Blight, A. R.
 (2009). Sustained‐release oral fampridine in multiple sclerosis: a randomised, double‐blind, controlled trial. Lancet, 373, 732–738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19249634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Goodman, A. D.
, 
Cohen, J. A.
, 
Cross, A.
, 
Vollmer, T.
, 
Rizzo, M.
, 
Cohen, R.
, … 
Blight, A. R.
 (2007). Fampridine‐SR in multiple sclerosis: a randomized, double‐blind, placebo‐controlled, dose‐ranging study. Multiple Sclerosis, 13, 357–368.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17439905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Horton, L.
, 
Conger, A.
, 
Conger, D.
, 
Remington, G.
, 
Frohman, T.
, 
Frohman, E.
, &amp; 
Greenberg, B.
 (2013). Effect of 4‐aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology, 80, 1862–1866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3908347</ArticleId>
            <ArticleId IdType="pubmed">23616154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Jensen, H.
, 
Ravnborg, M.
, 
Mamoei, S.
, 
Dalgas, U.
, &amp; 
Stenager, E.
 (2014). Changes in cognition, arm function and lower body function after slow‐release Fampridine treatment. Multiple Sclerosis, 20, 1872–1880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24852920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kido, Y.
, 
Matsson, P.
, &amp; 
Giacomini, K. M.
 (2011). Profiling of a prescription drug library for potential renal drug‐drug interactions mediated by the organic cation transporter 2. Journal of Medicinal Chemistry, 54, 4548–4558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3257218</ArticleId>
            <ArticleId IdType="pubmed">21599003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kim, Y. I.
, 
Goldner, M. M.
, &amp; 
Sanders, D. B.
 (1980). Facilitatory effects of 4‐aminopyridine on normal neuromuscular transmission. Muscle and Nerve, 3, 105–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6245354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Krupp, L. B.
, 
LaRocca, N. G.
, 
Muir‐Nash, J.
, &amp; 
Steinberg, A. D.
 (1989). The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology, 46, 1121–1123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2803071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Kurtzke, J. F.
 (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 33, 1444–1452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6685237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Limone, B. L.
, 
Sidovar, M. F.
, &amp; 
Coleman, C. I.
 (2013). Estimation of the effect of dalfampridine‐ER on health utility by mapping the MSWS‐12 to the EQ‐5D in multiple sclerosis patients. Health and Quality of Life Outcomes, 11, 105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3699372</ArticleId>
            <ArticleId IdType="pubmed">23799913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Lo, A. C.
, 
Ruiz, J. A.
, 
Koenig, C. M.
, 
Anderson, B. M.
, 
Olson, K. M.
, &amp; 
Triche, E. W.
 (2015). Effects of dalfampridine on multi‐dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non‐responders. Journal of the Neurological Sciences, 356, 77–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26139339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Macdonell, R.
, 
Nagels, G.
, 
Laplaud, D. A.
, 
Pozzilli, C.
, 
de Jong, B.
, 
Martins da Silva, A.
, … 
Soelberg Sorensen, P.
 (2016). Improved patient‐reported health impact of multiple sclerosis: The ENABLE study of PR‐fampridine. Multiple Sclerosis, 22, 944–954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26447066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Magnin, E.
, 
Sagawa, Y.
Jr
, 
Chamard, L.
, 
Berger, E.
, 
Moulin, T.
, &amp; 
Decavel, P.
 (2015). Verbal fluencies and fampridine treatment in multiple sclerosis. European Neurology, 74, 243–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26624899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Moran, P. J.
, &amp; 
Mohr, D. C.
 (2005). The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. Journal of Behavioral Medicine, 28, 35–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15887874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Pavsic, K.
, 
Pelicon, K.
, 
Ledinek, A. H.
, &amp; 
Sega, S.
 (2015). Short‐term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clinical Neurology and Neurosurgery, 139, 35–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26363365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Polman, C. H.
, 
Reingold, S. C.
, 
Banwell, B.
, 
Clanet, M.
, 
Cohen, J. A.
, 
Filippi, M.
, … 
Wolinsky, J. S.
 (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology, 69, 292–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3084507</ArticleId>
            <ArticleId IdType="pubmed">21387374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Prugger, M.
, &amp; 
Berger, T.
 (2013). Assessing the long‐term clinical benefit of prolonged‐release fampridine tablets in a real‐world setting: a review of 67 cases. Patient Related Outcome Measures, 4, 75–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3810492</ArticleId>
            <ArticleId IdType="pubmed">24187513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Pugliatti, M.
, 
Rosati, G.
, 
Carton, H.
, 
Riise, T.
, 
Drulovic, J.
, 
Vecsei, L.
, &amp; 
Milanov, I.
 (2006). The epidemiology of multiple sclerosis in Europe. European Journal of Neurology, 13, 700–722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16834700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Rabin, R.
, &amp; 
de Charro, F.
 (2001). EQ‐5D: a measure of health status from the EuroQol Group. Annals of Medicine, 33, 337–343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11491192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Rossini, P. M.
, 
Pasqualetti, P.
, 
Pozzilli, C.
, 
Grasso, M. G.
, 
Millefiorini, E.
, 
Graceffa, A.
, … 
Caltagirone, C.
 (2001). Fatigue in progressive multiple sclerosis: results of a randomized, double‐blind, placebo‐controlled, crossover trial of oral 4‐aminopyridine. Multiple Sclerosis, 7, 354–358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11795455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Ruck, T.
, 
Bittner, S.
, 
Simon, O. J.
, 
Gobel, K.
, 
Wiendl, H.
, 
Schilling, M.
, &amp; 
Meuth, S. G.
 (2014). Long‐term effects of dalfampridine in patients with multiple sclerosis. Journal of the Neurological Sciences, 337, 18–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24290498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Savin, Z.
, 
Lejbkowicz, I.
, 
Glass‐Marmor, L.
, 
Lavi, I.
, 
Rosenblum, S.
, &amp; 
Miller, A.
 (2016). Effect of Fampridine‐PR (prolonged released 4‐aminopyridine) on the manual functions of patients with Multiple Sclerosis. Journal of the Neurological Sciences, 360, 102–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26723984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Shi, R.
, &amp; 
Blight, A. R.
 (1997). Differential effects of low and high concentrations of 4‐aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience, 77, 553–562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9472411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Smith, K. J.
, 
Felts, P. A.
, &amp; 
John, G. R.
 (2000). Effects of 4‐aminopyridine on demyelinated axons, synapses and muscle tension. Brain, 123(Pt 1), 171–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10611131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Smits, R. C.
, 
Emmen, H. H.
, 
Bertelsmann, F. W.
, 
Kulig, B. M.
, 
van Loenen, A. C.
, &amp; 
Polman, C. H.
 (1994). The effects of 4‐aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology, 44, 1701–1705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7936300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>

Triche, E. W.
, 
Ruiz, J. A.
, 
Olson, K. M.
, &amp; 
Lo, A. C.
 (2016). Changes in cognitive processing speed, mood, and fatigue in an observational study of persons with multiple sclerosis treated with Dalfampridine‐ER. Clinical Neuropharmacology, 39, 73–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26818040</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
